{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:29:42Z","timestamp":1793255382126,"version":"4.5.0"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.2169\/internalmedicine.6312-25","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T22:08:38Z","timestamp":1767305318000},"page":"2002-2007","source":"Crossref","is-referenced-by-count":3,"title":["Olanzapine and the Spectrum of Drug-induced Diabetes: Unveiling Dual Risk Factors for Type 2 Diabetes and Acute-onset Ketoacidosis"],"prefix":"10.2169","volume":"65","author":[{"given":"Takahiko","family":"Nagamine","sequence":"first","affiliation":[{"name":"Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kolli P, Kelley G, Rosales M, Faden J, Serdenes R. Olanzapine pharmacokinetics: a clinical review of current insights and remaining questions. Pharmgenomics Pers Med 16: 1097-1108, 2023.","DOI":"10.2147\/PGPM.S391401"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat 15: 2559-2569, 2019.","DOI":"10.2147\/NDT.S209284"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Salviato Balb\u00e3o M, Cec\u00edlio Hallak JE, Arcoverde Nunes E, et al. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Ther Adv Psychopharmacol 4: 30-36, 2014.","DOI":"10.1177\/2045125313507738"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tamaroff J, Kilberg M, Pinney SE, McCormack S. Overview of atypical diabetes. Endocrinol Metab Clin North Am 49: 695-723, 2020.","DOI":"10.1016\/j.ecl.2020.07.004"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26: 1597-1605, 2003.","DOI":"10.2337\/diacare.26.5.1597"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Opp D, Hildebrandt C. Olanzapine-associated type 2 diabetes mellitus. Schizophr Res 56: 195-196, 2002.","DOI":"10.1016\/S0920-9964(01)00226-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wu H, Siafis S, Hamza T, et al. Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr Bull 48: 643-654, 2022.","DOI":"10.1093\/schbul\/sbac001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl) 207: 119-125, 2009.","DOI":"10.1007\/s00213-009-1639-8"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Wang J, Wu Q, Zhou Y, et al. The mechanisms underlying olanzapine-induced insulin resistance via the brown adipose tissue and the therapy in rats. Adipocyte 11: 84-98, 2022.","DOI":"10.1080\/21623945.2022.2026590"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R; Baltimore Longitudinal Study of Aging. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 52: 1475-1484, 2003.","DOI":"10.2337\/diabetes.52.6.1475"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ali RA, Jalal Z, Johal J, Paudyal V. Guideline adherence for cardiometabolic monitoring of patients prescribed antipsychotic medications in primary care: a retrospective observational study. Int J Clin Pharm 45: 1241-1251, 2023.","DOI":"10.1007\/s11096-023-01642-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sa YK, Yang H, Jung HK, et al. Olanzapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome with rhabdomyolysis: a case report. Endocrinol Metab (Seoul) 28: 70-75, 2013.","DOI":"10.3803\/EnM.2013.28.1.70"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Murakami H, Norita K, Ikeda A. Urinary retention triggered by urethritis in olanzapine-induced diabetic ketoacidosis. Intern Med 65: 497-502, 2026.","DOI":"10.2169\/internalmedicine.5880-25"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura M, Nagamine T. Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy. Intern Med 49: 2635-2637, 2010.","DOI":"10.2169\/internalmedicine.49.4397"},{"key":"15","unstructured":"15. Nagamine T. Olanzapine and diabetic ketoacidosis: what is the underlying mechanism? Innov Clin Neurosci 15: 11, 2018."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nagamine T. Atypical diabetes mellitus caused by olanzapine. Aust N Z J Psychiatry 55: 1207-1208, 2021.","DOI":"10.1177\/0004867420984232"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Avella J, Wetli CV, Wilson JC, Katz M, Hahn T. Fatal olanzapine-induced hyperglycemic ketoacidosis. Am J Forensic Med Pathol 25: 172-175, 2004.","DOI":"10.1097\/01.paf.0000127391.85007.f4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Jain AK, Shah A, Bhat G. Olanzapine-induced diabetic ketoacidosis: a reversible etiology overlooked in psychiatric patients. AACE Clin Case Rep 10: 14-16, 2023.","DOI":"10.1016\/j.aace.2023.10.006"},{"key":"19","unstructured":"19. Nagamine T. Olanzapine-induced endoplasmic reticulum stress induces atypical diabetes and diabetic ketoacidosis. Innov Clin Neurosci 19: 8-9, 2022."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ninagawa S, Tada S, Okumura M, et al. Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes. Elife 9: e60970, 2020.","DOI":"10.7554\/eLife.60970"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ozasa R, Okada T, Nadanaka S, et al. The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic \u03b2 cells by blocking PERK-mediated translational attenuation. Cell Struct Funct 38: 183-195, 2013.","DOI":"10.1247\/csf.13012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. Clin Drug Investig 41: 303-319, 2021.","DOI":"10.1007\/s40261-021-01000-1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tamaroff J, Kilberg M, Pinney SE, McCormack S. Overview of atypical diabetes. Endocrinol Metab Clin North Am 49: 695-723, 2020.","DOI":"10.1016\/j.ecl.2020.07.004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Fernandez-Egea E, Miller B, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 31: 154-159, 2011.","DOI":"10.1097\/JCP.0b013e31820fcea3"},{"key":"25","unstructured":"25. Nakamura M, Nagamine T. Metabolic changes in patients with schizophrenia switched from olanzapine to asenapine or clozapine. Innov Clin Neurosci 15: 11-12, 2018."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7: 64-77, 2020.","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Vuk A, Baretic M, Osvatic MM, Filipcic I, Jovanovic N, Kuzman MR. Treatment of diabetic ketoacidosis associated with antipsychotic medication: literature review. J Clin Psychopharmacol 37: 584-589, 2017.","DOI":"10.1097\/JCP.0000000000000772"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6312-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:13:58Z","timestamp":1785557638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6312-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":27,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6312-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"6312-25"}}